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Lymphoedema 
management in 
podoconiosis 
As researchers in the skin treat ment 
of podoconiosis, we were interested 
to read the Article by Henok Negussie 
and colleagues on lymphoedema 
management to prevent acute 
dermatolymphangioadenitis in 
podoconiosis (July, 2018).1 
We were, however, concerned 
about the interpretation of our cited 
trial on skin barrier function in those 
with podoconiosis in Ethiopia.2 
Negussie and colleagues state that 
our trial was a “small study”. In fact, 
it comprised 193 participants with 
podoconiosis. This number was 
established as follows: to achieve a 
power of 80% (two-sided t-test) with 
a 5% significance level, 64 par ticipants 
were required, divided equally be-
tween the two treatment groups. To 
allow detection of possible smaller 
effects on other secondary outcome 
measures, a target sample size of 
200 was chosen.
Negussie and colleagues also 
state that “small volumes of water 
with glycerol showed equivalent 
effects on skin barrier function to 
treatment with larger volumes of 
water”. This was not the case. At all 
three points on the lower outer leg 
and on the top of the foot, measures 
of transepidermal water loss and 
stratum corneum hydration using 
1 L of the 2% glycerine water soak 
(experimental group) compared 
with the 6 L water soak (control) 
indicated a statistically significant 
improvement over the 3-month 
trial. For example, on top of the 
foot, the estimated group difference 
in transepidermal water loss at the 
fourth visit was 1·751 (SE 0·0390) 
in favour of the experimental group 
(t=3·154; degrees of freedom [DF] 
189·580; p=0·002), indicating a 
greater reduction in transepidermal 
water loss in the experimental 
group. Similarly, at the same site, the 
estimated group difference in stratum 
corneum hydration at the fourth visit 
was –2·041 (SE 0·572) in favour of 
the experimental group (t=–3·565; 
DF 186·739, p<0·001), indicating a 
greater increase in stratum corneum 
hydration in the experimental group.
Furthermore,  Negussie and 
colleagues state “to our knowledge, 
GoLBeT is the first trial to assess 
the effects of a lymphoedema 
treatment package on the most 
important clinical consequence of 
lympho edema: the incidence of 
acute dermatolymphangioadenitis”. 
Our randomised controlled trial 
recorded work days lost due to 
adenolymphangitis (defined as 
an episode of inflammatory pain 
associated with the lymph nodes 
within a lymphoedematous leg 
which led patients to be bedridden 
or unable to work). At baseline, the 
mean number of work days lost in 
the previous month due to acute 
dermatolymphangioadenitis was 
4·56 for the control group and 
4·44 for the experimental group. At 
visit four, however, no participants in 
either group had lost any work days 
in the previous month due to acute 
dermatolymphangioadenitis.
Additionally, we propose that acute 
der mato lymphangioadenitis is only 
a surrogate of the primary failure 
point—stratum corneum barrier 
function—as one can address this 
profound systemic condition simply 
with topical treatment of water, soap, 
and petrolatum.
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